- Home
- OTLY vs FBRX Comparison
OTLY vs FBRX Comparison
Compare OTLY & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLY | FBRX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Sweden | United States |
| Employees | N/A | 16 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.1M | 379.3M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | OTLY | FBRX |
|---|---|---|
| Price | $10.91 | $28.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $15.50 | ★ $67.00 |
| AVG Volume (30 Days) | 69.7K | ★ 177.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.25 | $4.91 |
| 52 Week High | $18.84 | $35.62 |
Technical Indicators
Market Signals| Indicator | OTLY | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 47.06 |
| Support Level | $10.71 | $26.67 |
| Resistance Level | $12.44 | $32.12 |
| Average True Range (ATR) | 0.53 | 2.46 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 6.01 | 34.07 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).